@redescience @_idan_levin 2)The fact that the research is not dictated by gov funding nor by big pharma allows development of therapies like SupT1 cell infusion therapy, an #HIV therapy substantially cheaper than conventional drug based #HIV therapy (HAART). Here is a cost comparison estimation. https://t.co/L6Dm7vv1Tv
@redescience@\u idan\u levin 2）这项研究既不是由政府资助，也不是由大型制药公司主导，这一事实允许开发SupT1细胞输注疗法等疗法，这是一种比传统的基于药物的HIV疗法（HAART）便宜得多的HIV疗法。这是一个成本比较估算。https://t.co/L6Dm7vv1Tv